Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.
The purpose of this study is to determine the efficacy and the toxicities of the study drug PD0332991 in the treatment of patients with Stage IV non-small cell lung cancer with wildtype retinoblastoma protein (RB) and inactivated cyclin dependent kinase (CDK) N2A in the tumor.
Non-small Cell Lung Cancer
DRUG: PD0332991
Tumor Response by Direct RECIST Measurement, Response is a decrease in the sum of the longest diameters of the target lesions by more than 30% compared to the baseline., 6 months
Overall Survival, Median overall survival, 14 months|Progression-free Survival, Median progression-free survival., 12 months|Plasma Levels, Plasma levels of p16, phosphorylated RB and cyclin d1 in blood., 6 months|Grade of Study Drug Toxicity, The number of all toxicities and grades 3 and 4 (per CTCAE v3.0) toxicities that occured during the administration of the drug and during the follow up period., 24 months
The oral drug PD0332991 is a highly selective reversible inhibitor of cyclin-dependent kinases 4 \& 6 that is being studied for use in the treatment of advanced non-small cell lung cancer.